FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $407,192 | -93.0% | 192,072 | -84.3% | 0.00% | -100.0% |
| Q2 2023 | $5,816,283 | -52.6% | 1,221,908 | -43.3% | 0.00% | 0.0% |
| Q1 2023 | $12,280,816 | +154.7% | 2,154,529 | +350.9% | 0.00% | 0.0% |
| Q4 2022 | $4,821,780 | -35.8% | 477,877 | +42.7% | 0.00% | 0.0% |
| Q3 2022 | $7,507,000 | -6.3% | 334,945 | +3.6% | 0.00% | 0.0% |
| Q2 2022 | $8,012,000 | -37.1% | 323,339 | -1.6% | 0.00% | 0.0% |
| Q1 2022 | $12,736,000 | -43.2% | 328,511 | -14.3% | 0.00% | -50.0% |
| Q4 2021 | $22,422,000 | +56.9% | 383,197 | +58.9% | 0.00% | +100.0% |
| Q3 2021 | $14,293,000 | -37.9% | 241,171 | -9.0% | 0.00% | -50.0% |
| Q2 2021 | $23,008,000 | +26.6% | 265,092 | +20.3% | 0.00% | 0.0% |
| Q1 2021 | $18,176,000 | +28.7% | 220,446 | +42.0% | 0.00% | 0.0% |
| Q4 2020 | $14,120,000 | +266.5% | 155,287 | +61.1% | 0.00% | +100.0% |
| Q3 2020 | $3,853,000 | -8.4% | 96,417 | -21.4% | 0.00% | 0.0% |
| Q2 2020 | $4,207,000 | +33.4% | 122,618 | -13.7% | 0.00% | 0.0% |
| Q1 2020 | $3,154,000 | +35.1% | 142,023 | +19.1% | 0.00% | – |
| Q4 2019 | $2,335,000 | +19.7% | 119,285 | -5.0% | 0.00% | – |
| Q3 2019 | $1,951,000 | -30.6% | 125,609 | -9.3% | 0.00% | – |
| Q2 2019 | $2,810,000 | +32.2% | 138,418 | +14.4% | 0.00% | – |
| Q1 2019 | $2,126,000 | +268.5% | 120,954 | +169.2% | 0.00% | – |
| Q4 2018 | $577,000 | +29.7% | 44,925 | +64.4% | 0.00% | – |
| Q3 2018 | $445,000 | +9.3% | 27,327 | -23.9% | 0.00% | – |
| Q2 2018 | $407,000 | +303.0% | 35,911 | +245.3% | 0.00% | – |
| Q1 2018 | $101,000 | +180.6% | 10,400 | +73.0% | 0.00% | – |
| Q4 2017 | $36,000 | +300.0% | 6,013 | +177.4% | 0.00% | – |
| Q3 2017 | $9,000 | -81.2% | 2,168 | -92.3% | 0.00% | – |
| Q2 2016 | $48,000 | -5.9% | 28,320 | +0.3% | 0.00% | – |
| Q1 2016 | $51,000 | +18.6% | 28,228 | +119.2% | 0.00% | – |
| Q4 2015 | $43,000 | +616.7% | 12,880 | +1144.4% | 0.00% | – |
| Q4 2013 | $6,000 | – | 1,035 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |